Clinical Trial

A Study to Evaluate the Efficacy and Safety of AD-218

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-27; most recent amendment 2025-02-03.
Status change: Not Yet Recruiting → Recruiting 2022-11-27
Trial Details
NCT Number NCT05400317
Lead Sponsor Addpharma Inc.
Conditions Mixed Dyslipidemia
Enrollment 520 participants
Start Date 2022-07-27
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-05